S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:CYAD

Celyad Oncology Stock Forecast, Price & News

$3.67
-0.12 (-3.17%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.55
$3.68
50-Day Range
$3.67
$5.00
52-Week Range
$3.55
$10.31
Volume
8,951 shs
Average Volume
33,290 shs
Market Capitalization
$59.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.35
30 days | 90 days | 365 days | Advanced Chart
Receive CYAD News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.


Celyad Oncology logo

About Celyad Oncology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Headlines

Celyad Oncology S.A. ADR
August 21, 2021 |  barrons.com
Celyad Oncology S.A.
August 19, 2021 |  barrons.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYAD
Employees
83
Year Founded
N/A

Sales & Book Value

Annual Sales
$10 thousand
Book Value
$1.40 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$59.06 million
Optionable
Not Optionable

Company Calendar

Today
11/28/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

954th out of 1,391 stocks

Pharmaceutical Preparations Industry

450th out of 669 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Celyad Oncology (NASDAQ:CYAD) Frequently Asked Questions

Is Celyad Oncology a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celyad Oncology in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Celyad Oncology stock.
View analyst ratings for Celyad Oncology
or view top-rated stocks.

How has Celyad Oncology's stock been impacted by Coronavirus?

Celyad Oncology's stock was trading at $7.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYAD stock has decreased by 53.2% and is now trading at $3.67.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Celyad Oncology?

Celyad Oncology saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 7,200 shares, a drop of 60.0% from the October 31st total of 18,000 shares. Based on an average daily trading volume, of 24,100 shares, the days-to-cover ratio is presently 0.3 days.
View Celyad Oncology's Short Interest
.

What price target have analysts set for CYAD?

2 brokers have issued 12 month price targets for Celyad Oncology's shares. Their forecasts range from $15.00 to $15.00. On average, they expect Celyad Oncology's share price to reach $15.00 in the next year. This suggests a possible upside of 308.7% from the stock's current price.
View analysts' price targets for Celyad Oncology
or view top-rated stocks among Wall Street analysts.

Who are Celyad Oncology's key executives?

Celyad Oncology's management team includes the following people:
  • Filippo Joseph Petti, Director, Chief Executive & Financial Officer
  • Frederic Lehmann, VP-Clinical Development & Medical Affairs
  • David Gilham, Chief Scientific Officer
  • Peggy Sotiropoulou, Head-Research & Development
  • Charles Q. Morris, Chief Medical Officer

What other stocks do shareholders of Celyad Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX).

When did Celyad Oncology IPO?

(CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

What is Celyad Oncology's stock symbol?

Celyad Oncology trades on the NASDAQ under the ticker symbol "CYAD."

How do I buy shares of Celyad Oncology?

Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celyad Oncology's stock price today?

One share of CYAD stock can currently be purchased for approximately $3.67.

How much money does Celyad Oncology make?

Celyad Oncology has a market capitalization of $59.06 million and generates $10 thousand in revenue each year.

How many employees does Celyad Oncology have?

Celyad Oncology employs 83 workers across the globe.

What is Celyad Oncology's official website?

The official website for Celyad Oncology is www.celyad.com.

Where are Celyad Oncology's headquarters?

Celyad Oncology is headquartered at RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435.

How can I contact Celyad Oncology?

Celyad Oncology's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at (210) 039-4100 or via fax at 321-039-4141.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.